- Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vascular medicine (London, England). 2004 Academic Article GET IT
Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial.
The American Journal of Cardiology.
Times cited: 22